ePI on FHIR: Shaping the Future of Global Healthcare – Part 3
The session brings together key stakeholders from regulators, industry, and Gravitate Health to share the latest developments shaping the future of digital medicinal product information.
Building on previous sessions (Part I & II), this webinar will highlight progress in EU pharmaceutical legislation, provide updates from the European Medicines Agency (EMA) and a national competent authority (NCA), and reflect on lessons learned from the Gravitate Health, demonstrating how HL7 FHIR enables integration of ePI with patient data for more personalized, context-aware information delivery.
Attendees will gain insights into how standards-based approaches are enabling interoperability, enhancing patient engagement, and supporting the safer use of medicines across Europe. The session will also include perspectives from industry and outline the next steps for the Gravitate Health, including its sustainability and future evolution, marking a key milestone in advancing digital health innovation.
Registration is available
This session is open to all stakeholders across healthcare and regulatory sectors, concluding the series of similar global discussions.
Don’t miss this opportunity to stay at the forefront of ePI innovation and the evolving European health data landscape. Secure your place now:
Key takeaways from this session
- Trusted medicine information should be available in digital health environments.
- Developing ePI requires strong collaboration between regulators and stakeholders.
- Successful implementation depends on integration with national health systems.
agenda
- Welcome, Agenda & Introductions – Mrs Ronnie Mundair, Senior Director, GRS, Pfizer
- Strengthening FIFARMA’s commitment to healthcare – Mrs Yaneth Giha, Executive Director, FIFARMA
- LATAM ePI Playbook – Mr Diego Salas, Director, FIFARMA
- An update from Gravitate-Health – Prof. Anne Moen, Academic Coordinator, University of Oslo
- Advancing the National ePI Journey through Gravitate Health: An NCA perspective – Dr Erol Hofmans, Innovation Advisor, MEB
- FHIR ePI and the impact on global digital labeling strategies – Mr Craig Anderson, Business Product Director, J&J
- Closing Remarks – Mr Leonardo Semprun, Global Regulatory Policy Lead LatAm MSD & FIFARMA Regulatory Group Co-Chair
AGENDA & TOPICS
- General introductions and a Summary of key ePI global developments, Rie Matsui, APAC e-labeling EWG leader; Senior Director and Regional Labeling Head for APAC, Pfizer R&D Japan, & Anne Moen, Coordinator, Gravitate Health; Professor, University of Oslo, Norway
- Introduction to Gravitate Health, Giovanna Ferrari, Project Lead, Gravitate Health; Senior Director and Regional Labeling Head, Pfizer
- EMA – a regulators’ perspective (EU) and lessons learned from ePI pilot, Elizabeth Scanlan, ePI Product Owner, European Medicines Agency
- Jordan – a regulators’ perspective (Middle East) and demo of ePI system/app, Mohd. Rabi, IT Specialist, Drug Directorate, JFDA
- Taiwan – a regulator’s perspective (APAC) and future plans for e-labeling introduction, Chi Chung, Section Chief, TFDA
- Compendia – Felleskatalogen’s 20-year journey towards electronic product information (ePI) in Norway, Bente By Jansen, Managing director, Felleskatalogen AS
Panel Discussion & Q&A
The event concluded with a panel discussion, where attendees engaged with the speakers and asked questions about ePI’s potential in transforming global healthcare systems.
EVENT HIGHLIGHTS
WHEN? May 6, 2026
Time:
14:00–15:30 CET | 13:00–14:30 BST
WHERE? Virtual
ePI is on FHIR around the Globe – Past Webinars
This event builds on the insights from Gravitate Health’s two previous virtual events: ePI on FHIR – Part I, held in October 2024, and co-hosted with the Asia Partnership Conference of Pharmaceutical Associations (APAC); ePI on FHIR – Part II, held in March 2026, in partnership with FIFARMA, the Latin American Federation of the Pharmaceutical Industry.
